Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.
Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF’s focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, regenerative medicine, infectious diseases and digital health. These may include novel platform technologies to address so far undruggable targets, new generation vaccines and/or new biological entities, such as oncolytic virotherapy.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Nov 29, 2022
Rgenta Therapeutics
|
Series A | $52M | Biotechnology | — |
Apr 2, 2020
Rgenta Therapeutics
|
Seed | $20M | Biotechnology | Yes |
May 14, 2018
Acousia Therapeutics
|
Series B | €10M | Biotechnology | — |
Dec 11, 2017
Aelin Therapeutics
|
Series A | €27M | Biotechnology | — |
Dec 14, 2016
Acousia Therapeutics
|
Series A | €2.50M | Biotechnology | Yes |